Howard B. Goldman, MD, FACS, discusses innovations such as tibial nerve stimulation devices, pudendal nerve targeting, and alternative stimulation frequencies.

The investigators found a clear, dose-response relationship between patient-reported incontinence severity and the subsequent use of incontinence interventions such as artificial sphincters or bulking ...

Key Takeaways Expert panel developed guidelines for onabotulinumtoxinA use in OAB, emphasizing patient experience and compliance. Recommendations cover patient counseling, pre-procedure urinalysis, ...

In this episode of Pearls and Perspectives, host Amy Pearlman, MD, is joined by Joshua R. Gonzalez, MD —a board-certified urologist and sexual medicine specialist based in Los Angeles, California—for ...

David Stanley, MD, FACS, discusses current trends and unmet needs in the treatment of patients with kidney stones.

In a groundbreaking cross-border collaboration, Cleveland Clinic urologists recently completed the world's first remotely performed robot-assisted high-intensity focused ultrasound (HIFU) focal ...

Panelists discuss how the new PET technology could identify lymph node involvement not visible on conventional imaging, providing actionable information for surgical planning or indicating the need ...

Alicia K. Morgans, MD, MPH, highlights quality of life data from the phase 3 ARANOTE trial. The phase 3 ARANOTE trial (NCT04736199) showed that the addition of darolutamide (Nubeqa) to androgen ...

Panelists discuss the final BOND-3 trial results, highlighting intravesical cretostimogene’s strong efficacy, durable responses, and excellent safety profile in BCG-unresponsive carcinoma in situ (CIS ...

"Overall, these findings add to the growing body of evidence that [shows that] apalutamide may offer a survival advantage in real-world setting in patients with metastatic castration-sensitive ...

Panelists discuss how molecular imaging might help with complex renal mass decision-making, potentially identifying aggressive clear cell biology that would warrant radical rather than partial ...

MIST utilization increased from 7% in 2015 to 51% in 2022 among men aged 50 to 54. Recent data show that the use of minimally invasive surgical therapies (MISTs) for the management of benign prostatic ...